Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888992 · ClinicalTrials.gov registry record · NA
Technology-Enhanced Quitline Services to Prevent Smoking Relapse
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 1,785
- Enrollment target
NCT00888992: Completed NA study, sponsored by Indiana University.
NCT00888992 is a NA study that has completed, run by Indiana University. The registered enrollment target is 1,785 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (27% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00888992, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,785 participants
- Enrollment target
Study Summary
The purpose of this study is to see if automated telephone monitoring will enhance existing quitline services, such as Alere Wellbeing's Quit For Life program, and help people quit smoking. If successful, this intervention could be incorporated into existing quitline protocols and delivered to millions of people who are trying to quit smoking.
Interventions
- BEHAVIORAL Quitline Service + 10 automated monitoring calls
- BEHAVIORAL Quitline service + 20 automated monitoring calls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,785 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-03 |
| Phase | NA |
What the finished NCT00888992 record still lists
NCT00888992 is an interventional study that assigns participants to a tested intervention. Its 1,785 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (27% higher).
The record links to 0 conditions, and to 2 interventions - of which Quitline Service + 10 automated monitoring calls is the first listed.
NCT00888992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00888992 about?
NCT00888992 is a clinical study titled "Technology-Enhanced Quitline Services to Prevent Smoking Relapse". The purpose of this study is to see if automated telephone monitoring will enhance existing quitline services, such as Alere Wellbeing's Quit For Life program, and help people quit smoking. If successful, this intervention could be incorporated into existing quitline protocols and delivered to milli...
What is the current status of trial NCT00888992?
This trial is currently completed. It is a NA study. The enrollment target is 1,785 participants. The study started on 2010-04. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00888992?
The interventions under investigation include: Quitline Service + 10 automated monitoring calls (BEHAVIORAL), Quitline service + 20 automated monitoring calls (BEHAVIORAL).
Who is sponsoring clinical trial NCT00888992?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00888992's enrollment target sits among peer trials
1,785 59th of 2000 higher than 1,942 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05770570 · 1,785 participants · Phase 2
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
- NCT03067181 · 1,780 participants · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- NCT06526650 · 1,780 participants · NA
'Ai Pono Cooking Demonstrations
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia